SOTIO Completes Enrollment for Phase 3 Trial of DCVAC/PCa Immunotherapy – Prostate Cancer News Today
|
SOTIO Completes Enrollment for Phase 3 Trial of DCVAC/PCa Immunotherapy
Prostate Cancer News Today The Phase 3 trial evaluating the immunotherapy DCVAC/PCa in men with metastatic castration-resistant prostate cancer (mCRPC), has completed patient enrollment, according to trial sponsor, SOTIO. The treatment is being evaluated as an add-on to … |
